Table 3.

Distribution of ITGAX rs11574637 in patients with SSc and healthy controls.

	No.	Genotype, %			G Allele, %	Allelic Association
		GG	GT	TT		p	OR (95% CI)
French Caucasian
Controls	993	3.3	31.1	65.6	18.9
Patients with SSc	1011	4.0	32.9	63.1	20.4	0.22	1.1 (0.9–1.3)
Limited SSc	636	3.9	33.5	62.6	20.7	0.21	1.1 (0.9–1.3)
Diffuse SSc	315	3.8	32.1	64.1	19.8	0.59	1.06 (0.85–1.3)
Autoantibodies
Anti-centromere	367	4.4	33.2	62.4	21.0	0.22	1.1 (0.9–1.4)
Anti-topoisomerase I	246	4.1	30.9	65.0	19.5	0.75	1.0 (0.8–1.3)
US Caucasian
Controls	561	3.0	28.0	69.0	17.0
Patients with SSc	1013	3.9	30.9	65.2	19.4	0.1	1.17 (0.97–1.4)
Limited SSc	584	3.9	31.7	64.4	19.8	0.09	1.2 (0.97–1.5)
Diffuse SSc	377	4.2	30.0	65.8	19.2	0.22	1.16 (0.9–1.5)
Autoantibodies
Anti-centromere	287	2.4	32.8	64.8	18.8	0.36	1.13 (0.9–1.5)
Anti-topoisomerase I	166	5.4	33.1	61.4	22.0	0.039	1.37 (1.0–1.9)